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Abstract
Background: The aim of this study is to determine the prevalence and prognostic value of
elevated cardiac troponin (cTnT) and its association with clinical characteristics according to
renal function status in patients with stable heart failure.
Methods: In a prospective observational study, 152 consecutive patients from the Heart
Failure Clinic of the INCMNSZ were followed for a period of 42 months. All underwent
clinical evaluation, echocardiography, and determination of body composition by electric
bioimpedance to identify hypervolemia. Concentrations of cTnT were quantified by
immunoassay with electrochemoluminescence and ≥ 0.02 ng/mL levels were considered
elevated. Also glomerular filtration rate (eGFR) was estimated using the Cockcroft-Gault
equation.
Results: Elevated cTnT was significantly associated with increased all-cause mortality in the
observational period even after adjusting for eGFR < 60 mL/min/1.73 m2 and clinical find-
ings such as hypertension, functional class, loop diuretics, angiotensin converting enzyme
inhibitors, pulmonary pressure and hypervolemia in Cox regression analysis with a hazard
ratio of 4.58 (95% confidence interval: 1.84–11.45).
Conclusions: Heart failure patients with elevated cardiac-specific troponin T are at in-
creased risk of death independently of the presence of chronic kidney disease. (Cardiol J 2010;
17, 1: 42–48)
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Introduction
Heart failure (HF), a clinical syndrome with
diverse causes, is one of the commonest, most costly
and most incapacitating medical conditions. It accounts
for at least 20% of all hospital admissions [1, 2].
The structural and functional alterations caused
by HF are progressive and are often accompanied
by evidence of lesion and the death of myocardial
cells as part of the ventricular remodeling process
and/or apoptosis, regardless of the etiology [3, 4].
Damage to cardiac myocytes associated with
the progression of HF in the absence of ischemic
events explains elevated concentrations of tropo-
nin as a marker of acute or chronic subclinical myo-
cardial damage. This is the result of liberation of
cytosolic troponin after the rupture of the cardiac
myocytic membrane which is associated with in-
creased severity of the disease, diminished ejection
fraction and higher incidence of death [5–13].
In patients with kidney failure, who have a high
risk of developing heart failure [14], troponin con-
centrations are often elevated without evidence of
acute myocardial ischemia [15]. Thus, many of the
studies that evaluate elevated troponin concentra-
tions in HF exclude patients with elevated serum
creatinine. However, elevated troponin concentra-
tions have been associated with volume overload,
a common finding in patients with renal dysfunc-
tion as well as heart failure [14].
This study was designed to determine the
prevalence and prognostic value of elevated cardi-
ac troponin (cTnT) and its association with clinical
characteristics regardless of renal function status
in patients with chronic stable heart failure.
Methods
Study population
In a longitudinal, prospective and comparative
study, we consecutively studied a group of patients
with HF in the Heart Failure Clinic of the INCMNSZ
over a period of 42 months.
The population included men and women over
18 years of age with left and/or right ventricular dys-
function with optimal standard treatment (diuret-
ics, angiotensin converting enzyme inhibitors or an-
giotensin II antagonists, digitalis, beta-blockers and
aldosterone receptor antagonists). Patients were
ambulatory and had no admissions to the hospital
nor changes in their HF medication during the pre-
ceding three months.
Patients were excluded if they had: myoperi-
carditis; cardiac trauma; neoplastic and infiltrative
processes; chemotherapy; pulmonary embolism;
end-stage kidney failure or terminal liver failure;
recent (within three months) coronary syndromes
such as acute myocardial infarction, unstable angi-
na and/or coronary bypass surgery; uncontrolled
arrhythmias; use of vasodilators and/or intravenous
inotropic drugs.
The protocol was approved by the Committee
of Biomedical Investigation in Humans of the
INCMNSZ. Written informed consent was obtained
from each patient before inclusion in the study.
Laboratory diagnostics
Blood samples were collected for determina-
tion of serum levels of cTnT by a third-generation
electrochemoluminescence immunoanalysis (Elec-
sys autoanalyzer 2010, Roche Diagnostics, Man-
nheim, Germany). The minimum level of detection
was 0.010 ng/mL, and levels ≥ 0.02 ng/mL were
considered to be elevated [12]. Also serum electro-
lytes, lipid profile (total cholesterol, triglycerides,
HDL cholesterol and LDL cholesterol), microalbu-
minuria in 24 hour urine samples and levels of myo-
globin, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), lactic dehydrogenase
(LDH) and creatine kinase (CK) were determined.
Glomerular filtration rate (eGFR) was calculated by
Cockcroft-Gault equation. An abnormal glomerular
filtration rate was defined as < 60 mL/min/1.73 m2.
Echocardiographic measurements
Echocardiographic measurements were per-
formed using Hewlett Packard Sonos 5500 equip-
ment with M-mode, two dimensional and Doppler
images in parasternal long and short axis and two
and four chamber apical views. The cardiologist who
performed the echocardiograms did not have access
to the cTnT values.
Bioelectrical impedance analysis
Whole-body impedance was measured using
a BodyStat QuadScan 4000 tetrapolar and multiple
frequencies equipment (BodyStat Ltd, Isle of Man,
British Isles). Using 50 kHz frequency resistance
(R50), reactance (Xc50) and phase angle were ob-
tained by the BodyStat® Phase Angle Software Pro-
gram (version 1.0). The resistance and reactance
values were normalized by the height (H) of the
subjects, thus expressing both R/H and Xc/H in
Ohm/m and were plotted in the RXc graph (abscis-
sa R/H, ordinate Xc/H). The points that fell outside
the lower half of the reference curve of 75% of the
RXc graph were interpreted as hypervolemic. The
points that fell outside the right lower side of the
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reference curve of 75% on the RXc graph were clas-
sified as cachetic [16]. Also, the whole-body imped-
ance ratio at 200 kHz to that at 5 kHz (Z200/Z5) was
obtained; this served as an indicator of water dis-
tribution [17].
Statistical analysis
Continuous data is expressed as the mean val-
ue ± standard deviation and categorical variables
in percentages. Comparisons of all continuous vari-
ables between groups defined according to the
troponin T level (cTnT ≥ 0.02 ng/mL or cTnT
< 0.02 ng/mL) and eGFR (< 60 mL/min/1.73 m2 or
≥ 60 mL/min/1.73 m2 were calculated using analy-
sis of variance (ANOVA) statistics. The c2 test was
used for categorical variables to compare the four
groups.
The primary end point was all-cause mortality
stratified by cTnT levels and eGFR that were com-
pared by log-rank test and presented as Kaplan-
-Meier curve. A multivariable analysis was per-
formed with Cox proportional hazards model to
evaluate the prognostic value of cTnT (≥ 0.02 ng/
/mL versus cTnT < 0.02 ng/mL). The model includ-
ed all the variables statistically significant in the
univariate analysis and cTnT status.
Two-sided p values < 0.05 were considered to
be statistically significant. Statistical calculations
were performed using the statistical package SPSS
for Windows, version 16.0 (SPSS Inc., Chicago, IL,
USA).
Results
One hundred and fifty-two patients, with
a mean age of 63.64 ± 16.91 years, were included.
Men predominated (53.9%). In 39 (25.7%) cases,
cTnT ≥ 0.02 ng/mL was found and 21 (53.8%) of
them presented also eGFR< 60 mL/min/1.73 m2.
Systolic ventricular dysfunction predominated
in the high cTnT levels group (61.1%) and isolated
right ventricular dysfunction was also found in 5.6%
(Fig. 1).
Base-line demographic and clinical character-
istics according to cTnT status and glomerular fil-
tration rate are presented in Table 1. Patients with
both abnormal cTnT and eGFR had lower body mass
index, more dyspnea, significant water retention
measured by electric bioimpedance, lower phase
angle, a significantly greater proportion of excess
liquid in the extravascular space, worse functional
class, lower levels of hemoglobin, hematocrit, so-
dium and myoglobin, and greater kidney damage.
A higher percentage of patients with elevated cTnT
were on loop diuretics at the beginning of the study
than patients with normal cTnT, while more pa-
tients with normal cTnT were using thiazide diure-
tics. There were no other statistical differences
among other medications between the four groups.
Table 2 shows that the aortic diameter was low-
er in patients with cTnT ≥ 0.02 ng/mL and that pa-
tients in the group with both abnormal cTnT and
eGFR had higher pulmonary systolic pressure.
Kaplan-Meier curve for all-cause mortality by
troponin T level (cTnT ≥ 0.02 ng/mL or cTnT
< 0.02 ng/mL) and eGFR (< 60 mL/min/1.73 m2 or
≥ 60 mL/min/1.73 m2) is shown in Figure 2. The
crude mortality rate after a follow-up of 42 months
was 14.6% in the group with normal cTnT and
eGFR, 30% in the group with eGFR < 60 mL/min/
/1.73 m2, 73.7% in the group with both abnormal
cTnT and eGFR, and 77.8% in the group with cTnT
≥ 0.02 ng/mL.
The association between concentrations of
cTnT and overall mortality was tested by Cox mul-
tivariable analysis considering as categorical va-
riable (≥ 0.02 ng/mL versus cTnT < 0.02 ng/mL).
In a model including cTnT and demographic, clini-
cal and echocardiographic variables having a signif-
icant univariate relationship with outcome, this
marker had the strongest association with all-cause
mortality followed by hypervolemia on RXc graph
(Table 3).
Discussion
A high prevalence of elevated cTnT has been
described in acute or decompensate chronic HF [18,
19]. For this study, we excluded heart failure pa-
tients with unstable ischemic disease, as other
Figure 1. Prevalence of types of ventricular dysfunction
in patients with cardiac troponin T (cTnT) concentra-
tions ≥ 0.02 ng/mL.
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authors have recommended [20, 21]. Although we
found no statistically significant difference in cause
or type of heart failure, 25.7% of the patients had
elevated cTnT.
While elevations in cTnT have been reported
to be more frequent in cases of systolic heart fail-
ure, they have also been documented in cases of
diastolic heart failure, hypertrophic cardiomyopa-
thy and cardiac sudden death as evidence of chron-
ic subclinical damage in the absence of acute coro-
nary syndrome [12]. In our patients with chronic,
stable HF under optimal treatment we found no
difference in type of heart failure, including those
with isolated right heart failure secondary to chronic
obstructive pulmonary disease reported to be as-
sociated with a poor prognosis [9, 19].
Also in association with water retention, pa-
tients with elevated cTnT had a higher frequency
of hypervolemia. A similar situation has been ob-
served in patients in peritoneal dialysis, in which
hypervolemia markers with bioelectric impedance
vector analysis (BIVA) such as a smaller phase an-
gle and hypoalbuminemia were associated with
higher levels of B-type natriuretic peptide and
cTnT. In these cases, higher levels of cTnT asso-
ciated with increased volume overload and heart
rate could be attributed to excessive activation of
the rennin–angiotensin–aldosterone system and of
the central nervous system [18, 22].
Throughout the 42 month follow-up of the
study population, disregarding co-existent condi-
tions, mortality was higher in cTnT elevated cases
compared to those with normal cTnT, and higher
even than in patients with reduced eGFR (p <
< 0.0001). This is consistent with the findings of oth-
er authors, even in patients in hemodialysis [23–26].
The increased frequency of microalbuminuria in pa-
tients with higher cTnT levels might be explained
in part by kidney damage, but it is also a marker for
endothelial dysfunction, a condition often found in
cases of HF and associated with other indicators of
a poor prognosis [27]. In addition, this group with
elevated troponin levels tended to have higher pul-
monary artery systolic pressure and left ventricu-
lar diameters which are associated with a poor prog-
nosis [28].
Patients with elevated troponin had lower body
mass indices, as well as lower myoglobin levels,
compared to groups with low troponin. This sug-
gests cachexia (confirmed by BIVA) and the loss of
muscle mass that occurs in advanced cases of HF
[29–31]. This constellation of factors point to the
marked activation of neurohumoral systems with
liberation of cytokines such as tumor necrosis fac-Ta
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tor-alpha, interleukin-1 and interleukin-6 reported
in the literature [17, 32] and found in our patients.
These cytokines are associated with exacerbation
of symptoms and deterioration of functional class
in relation to a decrease in free fat mass and in-
crease in total and extracellular body water as-
sessed by BIVA.
Limitations of the study
Unfortunately, it was not possible to obtain end
point determinations of cTnT and myoglobin lev-
els, and the small sample size made it difficult to
establish greater differences in ventricular remod-
eling in the distinct types of HF and their echocar-
diographic characteristics and to determine whether
Figure 2. Kaplan-Meier cumulative curves for survival according to cardiac troponin T (cTnT) status and glomerular
filtration rate (eGFR).
it is equally sensitive to define cardiovascular mor-
tality in patients with elevated cTnT.
Conclusions
Mortality was significantly higher in the groups
with elevated cTnT, independent of chronic kidney
disease. Elevated troponin T levels were associat-
ed with worse clinical conditions, including greater
water retention and New York Heart Association
functional class. The prevalence of elevated cTnT
was independent of the type of heart failure. Volume
overload is a determining factor in the elevated
prevalence of cTnT, especially in cases of kidney
dysfunction.
Table 3. Univariate and multivariate predictors of overall mortality by Cox proportional hazard model.
Variables Univariate Hazard ratio Multivariate
(p) (95% CI) (p)
Age (years) 0.77 1.0 (0.97–1.02) 0.77
Hypertension (yes/no) 0.01 0.63 (0.26–1.51) 0.31
NYHA functional class (I–III) < 0.0001 1.45 (0.80–2.64) 0.22
ACEI (yes/no) 0.04 1.51 (0.60–3.77) 0.40
Loop diuretics (yes/no) 0.006 0.42 (0.15–1.16) 0.10
PAP [mm Hg] 0.02 1.02 (0.99–1.05) 0.21
cTnT ≥ 0.02 (yes/no) < 0.0001 4.58 (1.84–11.45) 0.001
eGFR < 60 mL/min/1.73 m2 0.003 1.27 (0.5–3.38) 0.63
Hypervolemia on RXc graph (yes/no) 0.0003 2.45 (1.04–5.79) 0.04
CI — confidence interval; NYHA — New York Heart Association; ACEI — angiotensin converting enzyme inhibitors; PAP — pulmonary arterial pressure;
RXc graph — resistance/reactance graph
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